Skip to main content
Evidence Snapshot

Thyroid hormone receptor beta

CHEMBL1947 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1947
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Thyroid hormone receptor beta as ChEMBL target CHEMBL1947, mapped to UniProt P10828. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Thyroid hormone receptor beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1947
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P10828
Thyroid hormone receptor beta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Thyroid hormone receptor beta matters

As of 2026-09-13

Thyroid hormone receptor beta is reviewed as Thyroid hormone receptor beta (UniProt P10828); Thyroid hormone receptor beta shows approved-linked disease relevance led by non-alcoholic steatohepatitis. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 6368 compounds, and 140 assays, with lead potency reaching pChEMBL 10.7.

Disease context
non-alcoholic steatohepatitis

Thyroid hormone receptor beta shows approved-linked disease relevance led by non-alcoholic steatohepatitis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include MB07811, RESMETIROM.

Start review with non-alcoholic steatohepatitis because it currently carries approved-linked support. Linked drugs include MB07811, RESMETIROM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 6368 compounds, and 140 assays for this target. The dominant activity type is IC50. CHEMBL291053 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL291053 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Thyroid hormone receptor beta matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P10828, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why non-alcoholic steatohepatitis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

6368
Total Compounds
140
Total Assays
8
Approved Drugs
IC50: 666.0, KI: 139.0, EC50: 215.0, KD: 31.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL291053
 10.7 IC50 Clinical
No preferred name
CHEMBL124126
 10.7 Ki —
No preferred name
CHEMBL289343
 10.6 IC50 —
No preferred name
CHEMBL125381
 10.5 Ki —
No preferred name
CHEMBL124205
 10.4 Ki —

Approved Drugs

Structure Compound First Approval
RESMETIROM
CHEMBL3261331
 2024
ROXADUSTAT
CHEMBL2338329
 2021
AMIODARONE
CHEMBL633
 1985
LEVOTHYROXINE
CHEMBL1624
 1982
LIOTHYRONINE
CHEMBL1544
 1956
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1947